Carbapenemase genes in clinical and environmental isolates of Acinetobacter spp. from Quito, Ecuador

PeerJ. 2024 Apr 25:12:e17199. doi: 10.7717/peerj.17199. eCollection 2024.

Abstract

Carbapenem-resistant Acinetobacter spp. is associated with nosocomial infections in intensive care unit patients, resulting in high mortality. Although Acinetobacter spp. represent a serious public health problem worldwide, there are a few studies related to the presence of carbapenemases in health care facilities and other environmental settings in Ecuador. The main aim of this study was to characterize the carbapenem-resistant Acinetobacter spp. isolates obtained from four hospitals (52) and from five rivers (27) close to Quito. We used the disc diffusion and EDTA sinergy tests to determine the antimicrobial susceptibility and the production of metallo β-lactamases, respectively. We carried out a multiplex PCR of gyrB gene and the sequencing of partial rpoB gene to bacterial species identification. We performed molecular screening of nine carbapenem-resistant genes (blaSPM, blaSIM, blaGIM, blaGES, blaOXA-23, blaOXA-24, blaOXA-51, blaOXA-58, and blaOXA-143) by multiplex PCR, followed by identification using sequencing of blaOXA genes. Our findings showed that carbapenem-resistant A. baumannii were the main species found in health care facilities and rivers. Most of the clinical isolates came from respiratory tract samples and harbored blaOXA-23, blaOXA-366, blaOXA-72, blaOXA-65, blaOXA-70, and blaOXA-143-like genes. The river isolates harbored only the blaOXA-51 and probably blaOXA-259 genes. We concluded that the most predominant type of carbapenem genes among isolates were both blaOXA-23 and blaOXA-65 among A. baumannii clinical isolates.

Keywords: Acinetobacter; Carbapenem resistance; Carbapenemases; Clinical isolates; Ecuador; OXA-143; OXA-51; Oxacilinases; Quito; River isolates.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acinetobacter Infections* / drug therapy
  • Acinetobacter Infections* / microbiology
  • Acinetobacter baumannii / drug effects
  • Acinetobacter baumannii / enzymology
  • Acinetobacter baumannii / genetics
  • Acinetobacter baumannii / isolation & purification
  • Acinetobacter* / drug effects
  • Acinetobacter* / enzymology
  • Acinetobacter* / genetics
  • Acinetobacter* / isolation & purification
  • Anti-Bacterial Agents / pharmacology
  • Bacterial Proteins* / genetics
  • Bacterial Proteins* / metabolism
  • Carbapenems / pharmacology
  • Cross Infection / microbiology
  • Ecuador / epidemiology
  • Humans
  • Microbial Sensitivity Tests
  • Multiplex Polymerase Chain Reaction
  • Rivers / microbiology
  • beta-Lactamases* / genetics
  • beta-Lactamases* / metabolism

Substances

  • beta-Lactamases
  • carbapenemase
  • Bacterial Proteins
  • Anti-Bacterial Agents
  • Carbapenems

Grants and funding

This work was supported by the Pontificia Universidad Católica del Ecuador project (No. L13341) and Universidad San Francisco de Quito (COCIBA Grant). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.